Literature DB >> 20566129

A new hemostasis valve for neuroendovascular procedures.

K Namba1, J K Song, Y Niimi, N S Heran, A Berenstein.   

Abstract

SUMMARY: A hemostasis valve is routinely used in neuroendovascular procedures to decrease the risk of thromboembolism (1,2) . Recently, a new hemostasis valve that is designed to minimize blood loss has been introduced. We report our initial experience in using this new hemostasis valve. In neuroendovascular procedures, a hemostasis valve is commonly used for continuous irrigation of guide and microcatheters to decrease the risk of thromboembolism(1,2,3). A conventional hemostasis valve has a rotating seal at the end, which is turned open or closed each time a wire or microcatheter/guidewire is introduced or extracted. Often this results in significant back bleeding. When a rotating seal is adjusted suboptimally during a wire or microcatheter manipulation, leakage of pressurized saline from the end of a hemostasis valve results in stagnation of blood within a guiding catheter, which becomes a potential source of emboli during a procedure. The Guardian Haemostasis Valve (Zerusa Limited, Galway, Ireland) is a new hemostasis valve that is designed to minimize blood loss during interventional procedures by minimizing the opening time of the valve during wire or microcatheter insertion. A continuous sealing mechanism during wire or microcatheter positioning minimizes blood loss and stagnation of blood within the guide catheter. We report our initial experience with the Guardian hemostasis valve.

Entities:  

Year:  2007        PMID: 20566129      PMCID: PMC3329166          DOI: 10.1177/159101990701300106

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  1 in total

1.  "Two-coil technique" for embolization of small internal carotid artery aneurysms incorporating the origin of the anterior choroidal artery.

Authors:  Young Jin Heo; Ku Hyun Yang; Sung Chul Jung; Jung Cheol Park; Deok Hee Lee
Journal:  Interv Neuroradiol       Date:  2016-02-16       Impact factor: 1.610

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.